A leading provider of
innovative DNA Screening solutions
IGH/FGFR3 Translocation, Dual Fusion LPH030 - Detail
The t(4;14) (p16.3;q32.3) translocation is found in approximately 10% of myeloma patients and results in the deregulation of at least two genes. These are MMSET (Multiple Myeloma SET domain containing protein also known as WHSC1) and FGFR3 (fibroblast growth factor receptor 3) with the formation of a fusion product between MMSET and the immunoglobulin heavy chain (IGH) locus and overexpression of FGFR3. The majority of the breakpoints on chromosome 4 occur within the MMSET locus resulting in a fusion gene where the 5' exons of MMSET are replaced with the VDJ region of the heavy chain locus. FGFR3 lies at least 50kb from the breakpoints after translocation to chromosome 14 and . Other studies state that the breakpoints on chromosome 4 lie in a 113kb region between FGFR3 and MMSET exon 52. The breakpoint on chromosome 14 is almost exclusively in or near the switch region of the IGH locus.
Reference:/Bibliographie/Literatur/Bibliografia
- Sibley K et al (2002) Br J Haematol 118: 514-520
- Kyats JJ et al (2003) Blood 101: 1520-1529
IGH/FGFR3 Translocation, Dual Fusion
Cat. No. LPH 030-S (5 tests)
Cat. No. LPH 030 (10 tests)
This webpage could contain information on product details or information not valid in your country or region. Please be aware that we do not take any responsibility for accessing such information, which may not comply with any legal process, regulation, registration or usage in the country of your origin. If you are a resident of a country other than those to which this site is directed, contact your local Cytocell distributor to obtain the appropriate product information for your country of residence.
Developed &produced in the UK